502 filings
Page 6 of 26
CT ORDER
mb0uwqrfvx0qeqq
27 Aug 12
Confidential treatment order
12:00am
8-K
iniz5v3upo 3cqcrhkic
1 Aug 12
NPS Pharmaceuticals Reports Second Quarter 2012 Financial Results
12:00am
8-K
c1bp2mvapbyww gx2z9
2 Jul 12
NPS Pharmaceuticals Announces Amended Royalty Agreement with Amgen
12:00am
8-K
rx8ni6ymrn9w7t
21 May 12
Submission of Matters to a Vote of Security Holders
12:00am
ARS
7x6ysqbuvfoavn9a b6
10 May 12
Annual report to shareholders
12:00am
8-K
aqb4e
3 May 12
NPS Pharmaceuticals Reports First Quarter 2012 Financial Results
12:00am
CT ORDER
1un0hac5
13 Mar 12
Confidential treatment order
12:00am
8-K
2cwnmz7fx0oukpqii6jw
29 Feb 12
NPS Pharmaceuticals Appoints Georges Gemayel, Ph.D., to Board of Directors
12:00am
8-K
qrjz13 o5
15 Feb 12
NPS Pharmaceuticals Reports 2011 Year-End Financial Results and 2012 Cash Burn Guidance
12:00am
8-K
tdcohmy bb
7 Nov 11
NPS Pharmaceuticals Announces Positive Top-Line Results from Pivotal Phase 3 REPLACE Study of NPSP558 in Hypoparathyroidism
12:00am
8-K
76z9ys0c kst
3 Nov 11
NPS Pharmaceuticals Reports Third Quarter 2011 Financial Results and Improves Cash Burn Guidance
12:00am
8-K
exhonw9uc7 y1m7l8
31 Oct 11
Phase 3 GATTEX® (teduglutide) Data Highlight Potential New Treatment for Adults with Short Bowel Syndrome
12:00am
CT ORDER
npgw1muc2bin
27 Sep 11
Confidential treatment order
12:00am
EFFECT
k7s4smzr36iu
15 Aug 11
Notice of effectiveness
12:00am
8-K
zmv8b0rf2
15 Aug 11
NPS Pharmaceuticals Announces Amended Amgen Agreement and Plan to Retire Sensipar-Backed Series B Notes
12:00am